国家医保局：2024年中国药企海外授权交易总额超500亿美元

Group 1 - The core viewpoint of the article is the release of measures by the National Healthcare Security Administration and the National Health Commission to promote the global market development of innovative drugs [1][2] - The measures emphasize leveraging China's vast production capacity, large market, and rich experience to actively promote the achievements of Chinese innovative drug development in international cooperation [1] - The document encourages regions with conditions to explore building global innovative drug trading platforms targeting Southeast Asia, Central Asia, and other Belt and Road countries, enhancing international promotion [1] Group 2 - In 2024, Chinese pharmaceutical companies completed over 90 overseas licensing transactions, totaling more than $50 billion [1] - The measures highlight three basic considerations: building platforms to assist in expanding overseas markets, supporting innovative enterprises' rapid development, and providing price support for innovative drugs going abroad [2] - The National Healthcare Security Administration plans to adopt a price confidentiality mechanism for innovative drugs, especially for those in commercial insurance directories, to facilitate their overseas listing [2]